Cardiovascular
-
Collaboration in cardiovascular and metabolic medicine
Cardialysis and Sticares InterACT entered into a collaboration to provide drug development consulting services in the field of cardiovascular and metabolic medicine. Both CROs have substantial experience and success in the execution of clinical …
Cardiovascular | 10 December 2010
-
Poor glucose control associated with cardiovascular risk
Sanofi-aventis announced the baseline results of a worldwide prospective longitudinal epidemiologic study designed to assess the predictive value of risk factors for developing cardiovascular disease and Type 2 diabetes – INSPIRE-ME IAA (INternati…
Cardiovascular | 12 October 2010
-
Diagnostics help curtail cardiovascular disease
With an increasing focus on diagnostics, the treatment and management of cardiovascular disease (CVD) is taking a new direction, according to experts presenting at the Roche Asia Pacific Cardiology Forum, which is being held just prior to the World C…
Cardiovascular | 28 June 2010
-
Big Pharma Struggles to Benefit from Increased CVD Drug Usage
Pharmaceutical (Pharma) companies will struggle to profit from the Cardiovascular Disease (CVD) market over the next decade despite growing drug usage, according to Datamonitor. It is predicted that the CVD pharma market will grow from US$99 billion …
Cardiovascular | 17 March 2010
-
Blood Pump for Simulating the Ventricular Action of the Heart
Harvard Apparatus has introduced the Pulsatile Blood Pump for cardiovascular and haemodynamic studies on mice, rats, and larger animals. The pump is ideal for moving emulsions, suspensions, and non-Newtonian fluids such as blood. It simulates the …
Cardiovascular | 11 September 2009
-
ViroMed Completes Trial for Cardiovascular Disease Treatment
ViroMed has announced that the final injections for patients enrolled in a Phase I clinical trial in China for VM202, the company’s proprietary DNA medicine for various types of cardiovascular disease (CVD), have been completed. The clinical tri…
Cardiovascular | 11 June 2009
-
Onglyza Cardiovascular Profile Acceptable to FDA
The US Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee have determined that the data supporting the new drug application for Onglyza (saxagliptin) for the treatment of adults with type two diabetes is suffic…
Cardiovascular | 08 April 2009
-
Philips Leads European Sonodrugs Project
Philips Electronics says it is leading a European project to develop drug delivery technologies that could significantly impact the treatment of cancer and cardiovascular disease. By allowing drugs to be delivered to disease sites via the patient…
Cardiovascular | 09 February 2009
-
New Core Laboratories Joint Venture
Vibgyor Scientific Research, genae associates, Cardiovascular Center Aalst and Core Laboratories have reached an agreement to form a joint venture called imaeon. imaeon will initially focus on the performance of medical images analysis for clini…
Cardiovascular | 01 October 2008
-
Prasugrel, Clopidogrel head-to-head study
A new, pre-specified analysis of the landmark Phase III head-to-head Triton-Timi 38 study showed certain patients were 35% less likely to have a recurrent event (composite endpoint of heart attack, stroke or cardiovascular death) than those who took …
Cardiovascular | 25 August 2008
